Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

1.070 -0.030 (-2.73%)
Streaming Delayed Price Updated: 12:06 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genprex Inc

< Previous 1 2 3 4 5 6 7 Next >
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Chief Medical Officer Featured Guest on Latest Bell2Bell Release
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System
Via Investor Brand Network
Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Video Featuring Clinical Trial Patient Sharing Study Experience
Via Investor Brand Network
Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial
Via ACCESSWIRE
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives SRC Approval to Advance to Phase 2 Portion of REQORSA(R) Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Results of Phase 1 Clinical Trial Will Be Published at ASCO Meeting
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data with NPRL2 Gene Therapy
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate and Present at Upcoming May Industry and Investor Conferences
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16.... 
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Data Supporting Therapeutic Potential of Its Non-Viral Delivery System
Via Investor Brand Network
Genprex Touts Encouraging Preclinical Data From Lung Cancer Candidate
Genprex Inc (NASDAQ: GNPX) announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene).  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket
Gainers Clearmind Medicine Inc. (NASDAQ: CMND) jumped 69.3% to $0.8480 in pre-market trading after dropping 12% on Tuesday. Clearmind Medicine recently announced a $3.5 million public offering priced... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Research Findings, Additional Support for REQORSA(R) and Its Therapeutic Potential
Via Investor Brand Network
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Statement Regarding FDA Initiative to Accelerate Approval Process for Gene Therapies
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Barcelona Conference
Via Investor Brand Network
Genprex’s Gene Therapy: Potential Breakthrough for Diabetes and Lung Cancer
Genprex’s Gene Therapy: Potential Breakthrough for Diabetes and Lung Cancer 
Via News Direct
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences
Via Investor Brand Network
S&P 500 Rises Over 0.5%; US Pending Home Sales Increase Sharply
U.S. stocks traded higher toward the end of trading, with the NASDAQ Composite gaining around 100 points on Monday. The Dow traded up 0.40% to 32,949.23 while the NASDAQ rose 0.93% to 11,500.59. The... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises 80 Points; TEGNA Shares Plunge
U.S. stocks traded higher midway through trading, with the NASDAQ Composite gaining around 80 points on Monday. The Dow traded up 0.15% to 32,867.61 while the NASDAQ rose 0.70% to 11,475.20. The S&P... 
Via Benzinga
Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.